Project Grant R43HL176343
Award Date
9/20/24
Completion Date
2/28/25
Dollars Obligated
$307K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Novomedix LLC (XQYMHKGDMU75)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92126, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding the development of a novel drug candidate to treat idiopathic pulmonary fibrosis (IPF). The award of $356,250 will support a two-phase project by Vasarya Therapeutics, Inc. to perform affinity maturation and liability assessment on a tool compound called VSR-H5, which has demonstrated the ability to selectively target and inhibit...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $542,402 Project Grant under CFDA Program 93.837 - Cardiovascular Diseases Research to a research collaboration between Henry Ford Health and Michigan State University Health Sciences. The grant aims to screen novel compounds that can reverse profibrotic gene signatures associated with idiopathic pulmonary fibrosis (IPF), a fatal lung disease with limited treatment options. The project involves three key objectives: 1) in silico...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $464,121 to The Medical University of South Carolina to develop peptides derived from collagen XVIII for the treatment of pulmonary fibrosis. The project aims to simultaneously test the identified peptides in preclinical models of fibrosis, identify a lead candidate, characterize its efficacy, conduct dose escalation...
The Project Grant award for R43HL176301, titled "Stiffness Measurements in Human Lung Slices to Evaluate Therapeutic and Preventive Potentials of Anti-Fibrotic Drugs," was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The $306,748 award will be used by Mechanobiologix LLC to develop a stiffness-based drug discovery platform for idiopathic pulmonary fibrosis (IPF). The project aims to...
This federal Project Grant award of $805,845 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and testing of novel lung-targeted therapeutic delivery systems. The goal is to create "precision drug delivery systems" that can actively transport anti-fibrotic agents directly into lung tissue to treat conditions like idiopathic pulmonary fibrosis. Key products/services include engineering...
This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding research at Northwestern University to investigate the role of mitochondrial metabolism in alveolar epithelial cell differentiation and the development of lung fibrosis. The $616,000 award, effective September 1, 2024 through August 31, 2029, will support experiments using genetic mouse models to determine how mitochondrial...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $122,788 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), with a project period from September 15, 2024 to June 30, 2026. The goal of this project is to establish a pharmacokinetic model for absolute quantification of pulmonary perfusion and microvascular parameters, and validate this model in large animal...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,410,668 to The Methodist Hospital Research Institute (HMRI) to investigate the role of cyclin-dependent kinase 9 (CDK9) in the pathogenesis and treatment of idiopathic pulmonary fibrosis (IPF). The research aims to elucidate the molecular mechanisms by which CDK9 regulates IPF, screen CDK9 inhibitors for anti-fibrotic efficacy, and develop an inhalable CDK9...